Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe Road, Zhengzhou, 450000, Henan, China.
Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Clin Transl Oncol. 2022 Dec;24(12):2409-2419. doi: 10.1007/s12094-022-02911-x. Epub 2022 Aug 13.
To compare the effect of intraoperative radiotherapy (IORT) and no radiotherapy in early stage low-risk breast cancer patients undergoing breast-conserving surgery.
According to the criteria recommended by ASTRO for patients eligible for IORT, we retrospectively selected women with early stage low-risk breast cancer who underwent breast-conserving surgery from 2010 to 2019 from the SEER database. Propensity score matching was used to balance the differences in baseline characteristics. The Kaplan-Meier method was used to calculate the overall survival (OS) and breast cancer-specific survival (BCSS) of patients, and the log-rank test was used to compare the differences.
A total of 20,245 patients were included in the analysis, including 1738 in the IORT group and 18,507 in the no radiotherapy group, with a median follow-up of 41 months. Before matching, the 5-year OS rates of the IORT group and the no radiotherapy group were 95.5% and 85.7% (p < 0.001), respectively, and the 5-year BCSS rates of the two groups were 99.6% and 98.3% (p < 0.001), respectively. After matching, the 5-year OS rates were 95.6% and 90.3% (p < 0.001) in the IORT group and the no radiotherapy group, respectively, and the 5-year BCSS rates were 99.5% and 99.1% (p = 0.028), respectively. Cox multivariate analysis of the original data showed that radiotherapy was an independent prognostic factor for both OS and BCSS (p < 0.05).
For patients aged 50 years or older with early stage low-risk breast cancer, IORT may be a better option, with improved BCSS compared to the elimination of radiotherapy. The study could not draw conclusions on OS, because underlying diseases may be unevenly distributed between the two groups.
比较早期低危乳腺癌保乳手术后接受术中放疗(IORT)与不接受放疗的效果。
根据 ASTRO 推荐的 IORT 适用患者标准,我们从 SEER 数据库中回顾性选择了 2010 年至 2019 年接受保乳手术的早期低危乳腺癌女性患者。采用倾向评分匹配法平衡基线特征差异。采用 Kaplan-Meier 法计算患者的总生存率(OS)和乳腺癌特异性生存率(BCSS),并采用对数秩检验比较差异。
共纳入 20245 例患者,其中 IORT 组 1738 例,无放疗组 18507 例,中位随访时间为 41 个月。匹配前,IORT 组和无放疗组的 5 年 OS 率分别为 95.5%和 85.7%(p<0.001),5 年 BCSS 率分别为 99.6%和 98.3%(p<0.001)。匹配后,IORT 组和无放疗组的 5 年 OS 率分别为 95.6%和 90.3%(p<0.001),5 年 BCSS 率分别为 99.5%和 99.1%(p=0.028)。原始数据的 Cox 多因素分析显示,放疗是 OS 和 BCSS 的独立预后因素(p<0.05)。
对于年龄 50 岁及以上的早期低危乳腺癌患者,与消除放疗相比,IORT 可能是一种更好的选择,可改善 BCSS。该研究未能得出关于 OS 的结论,因为两组之间的基础疾病可能分布不均。